Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer

Completed · Phase 3

Conditions studied: Carcinoma, Non-Small-Cell Lung

In brief

The objective of this phase III trial is to establish statistical equivalence in terms of efficacy (best overall response rate \[ORR\], proportion of patients with complete response \[CR\] plus partial response \[PR\]) until 18 weeks of first-line treatment with BI 695502 plus chemotherapy versus Avastin® plus chemotherapy followed by maintenance monotherapy with either BI 695502 or Avastin®.

Key facts

Study ID

NCT02272413

Run by

Boehringer Ingelheim

People needed

671

Starts

2015-07-08

Expected to finish

2018-11-16

Last updated by the study team

2020-01-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients aged >=18 years with histologically or cytologically confirmed advanced nonsquamous non-small cell lung cancer (nsNSCLC). Mixed tumors should be categorized according to the predominant histology.
• Note: NSCLC should be predominantly nonsquamous. Recurrent or metastatic disease (Stage IV) with an indication for therapy with paclitaxel + carboplatin + Avastin®.
• Patients harboring tumors with unknown or without activating epidermal growth factor receptor (EGFR) / anaplastic lymphoma receptor tyrosine kinase (ALK) mutation maybe included provided chemotherapy is standard of care. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 based on independent central review.
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.
• Adequate hepatic, renal, and bone marrow function:
• Life expectancy > 6 months based on clinical judgment. Further inclusion criteria apply.

You may not qualify if…

• Prior therapy with monoclonal antibodies or small molecule inhibitors against Vascular Endothelial Growth Factor (VEGF) or VEGF receptors, including Avastin®.
• Prior systemic therapy for metastatic disease. Prior systemic anticancer therapy or radiotherapy for locally advanced nsNSCLC if completed <12 months prior to Screening.
• Previous malignancy other than NSCLC in the last 5 years except for basal cell cancer of the skin or pre-invasive cancer of the cervix.
• Symptomatic brain metastasis. Diagnosis of small cell carcinoma of the lung, squamous cell carcinoma of the lung, NSCLC not specified (NS) or NSCLC not otherwise specified(NOS).
• Any unresolved toxicity > Common Toxicity Criteria Grade 1 (except alopecia) from previous anticancer therapy (including radiotherapy).
• History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding. Thrombotic or hemorrhagic event =< 6 months prior to Screening. Further exclusion criteria apply.

Where it is running

• Comprehensive Blood and Cancer Center — Bakersfield, California, United States
• Lalita Pandit, M.D., Inc. — Fountain Valley, California, United States
• Southern California Oncology Research Alliance — Los Angeles, California, United States
• Innovative Clinical Research, Inc. — Whittier, California, United States
• Ashland Bellefonte Cancer Center — Ashland, Kentucky, United States
• Reliant Medical Group — Worcester, Massachusetts, United States
• Detroit Clinical Research Center — Owosso, Michigan, United States
• Carolinas Cancer Care — Charlotte, North Carolina, United States
• CENIT - Centro de Neurociencias, Investigacion y Tratamiento — Ciudad Autonoma Buenos Aires, Argentina
• Sanatorio Delta — Rosario, Argentina
• Sanatorio Parque — Rosario, Argentina
• Centro Oncológico de Rosario — Rosario, Argentina
• CPCO - Centro de Pesquisa Clinica em Oncologia — Cachoeiro de Itapemirim, Brazil
• Hospital do Cancer do Ceara — Fortaleza, Brazil
• Pronutrir — Fortaleza, Brazil
• Hospital de Carida de de Ijui - CACON — Ijuí, Brazil
• Hospital Bruno Born — Lajeado, Brazil
• Hospital da Cidade de Passo Fundo — Passo Fundo, Brazil
• Universidade de Caxias do Sul - IPCEM - Inst. de Pesq.clilni — Petrópolis, Brazil
• Irmandade da Santa Casa de Misericórdia de Porto Alegre — Porto Alegre, Brazil
• Hospital de Clínicas de Porto Alegre — Porto Alegre, Brazil
• CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia — Santo André, Brazil
• ICAVC - Instituto do Cancer Arnaldo Vieira de Carvalho — São Paulo, Brazil
• ICESP - Instituto do Cancer do Estado de Sao Paulo — São Paulo, Brazil
• Pacific Cancer Medical Center, Inc. — Anaheim, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.